NASDAQ:BIIB - Biogen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $325.3650 -0.28 (-0.09 %) (As of 03/19/2019 02:38 PM ET)Previous Close$325.6450Today's Range$324.00 - $327.7552-Week Range$249.17 - $388.67Volume553,255 shsAverage Volume1.07 million shsMarket Capitalization$64.00 billionP/E Ratio12.42Dividend YieldN/ABeta1.09 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Receive BIIB News and Ratings via Email Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BIIB Previous Symbol CUSIP09062X10 CIK875045 Webwww.biogen.com Phone617-679-2000Debt Debt-to-Equity Ratio0.46 Current Ratio2.32 Quick Ratio2.04Price-To-Earnings Trailing P/E Ratio12.42 Forward P/E Ratio11.34 P/E Growth1.24 Sales & Book Value Annual Sales$13.45 billion Price / Sales4.76 Cash Flow$31.3152 per share Price / Cash Flow10.39 Book Value$64.68 per share Price / Book5.03Profitability EPS (Most Recent Fiscal Year)$26.20 Net Income$4.43 billion Net Margins32.94% Return on Equity40.53% Return on Assets21.34%Miscellaneous Employees7,800 Outstanding Shares196,710,000Market Cap$64.00 billion Next Earnings Date4/23/2019 (Estimated) OptionableOptionable Biogen (NASDAQ:BIIB) Frequently Asked Questions What is Biogen's stock symbol? Biogen trades on the NASDAQ under the ticker symbol "BIIB." How were Biogen's earnings last quarter? Biogen Inc (NASDAQ:BIIB) released its earnings results on Tuesday, January, 29th. The biotechnology company reported $6.99 earnings per share for the quarter, beating analysts' consensus estimates of $6.72 by $0.27. The biotechnology company earned $3.53 billion during the quarter, compared to the consensus estimate of $3.39 billion. Biogen had a net margin of 32.94% and a return on equity of 40.53%. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.26 EPS. View Biogen's Earnings History. When is Biogen's next earnings date? Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, April 23rd 2019. View Earnings Estimates for Biogen. How can I listen to Biogen's earnings call? Biogen will be holding an earnings conference call on Wednesday, April 24th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. What guidance has Biogen issued on next quarter's earnings? Biogen issued an update on its FY19 earnings guidance on Tuesday, January, 29th. The company provided EPS guidance of $28-29 for the period, compared to the Thomson Reuters consensus estimate of $27.98. The company issued revenue guidance of $13.6-13.8 billion, compared to the consensus revenue estimate of $13.63 billion.Biogen also updated its FY 2019 guidance to $28.00-29.00 EPS. What price target have analysts set for BIIB? 26 brokerages have issued 12 month price targets for Biogen's shares. Their forecasts range from $262.15 to $436.00. On average, they expect Biogen's share price to reach $370.2750 in the next year. This suggests a possible upside of 13.7% from the stock's current price. View Analyst Price Targets for Biogen. What is the consensus analysts' recommendation for Biogen? 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 9 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biogen. What are Wall Street analysts saying about Biogen stock? Here are some recent quotes from research analysts about Biogen stock: 1. HC Wainwright analysts commented, "Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (2/19/2019) 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $400 12-month price target. Biogen hosted a webcast this morning to outline its strategy in multiple sclerosis (MS), focusing on the pipeline as well as lifecycle management for the $9B base business. We saw detailed commentary about specific lifecycle management plans as most important. We think BIIB098 could be another option for new patients or Tecfidera switches. Although investors remain focused on aducanumab, we think understanding long-term MS growth is of similar importance." (12/12/2018) 3. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call and BAN2401 data last week." (7/31/2018) Has Biogen been receiving favorable news coverage? News headlines about BIIB stock have trended positive on Tuesday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biogen earned a news impact score of 2.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days. Who are some of Biogen's key competitors? Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN) and Acceleron Pharma (XLRN). What other stocks do shareholders of Biogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), Celgene (CELG), Netflix (nflx), NVIDIA (NVDA), Alibaba Group (BABA), Amgen (AMGN), Tesla (TSLA), Allergan (AGN), Alphabet (GOOG) and Intel (INTC). Who are Biogen's key executives? Biogen's management team includes the folowing people: Mr. Michel Vounatsos, CEO & Director (Age 57)Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)Ms. Susan H. Alexander, Exec. VP, Chief of Legal & Corp. Services and Corp. Sec. (Age 62)Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53) Who are Biogen's major shareholders? Biogen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.22%), Oregon Public Employees Retirement Fund (7.10%), FMR LLC (1.87%), Northern Trust Corp (1.48%), Geode Capital Management LLC (1.38%) and Bank of New York Mellon Corp (1.14%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen. Which institutional investors are selling Biogen stock? BIIB stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, MERIAN GLOBAL INVESTORS UK Ltd, Canada Pension Plan Investment Board, Macquarie Group Ltd., Acadian Asset Management LLC, Nomura Asset Management Co. Ltd., Eaton Vance Management and First Quadrant L P CA. View Insider Buying and Selling for Biogen. Which institutional investors are buying Biogen stock? BIIB stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, Prudential Financial Inc., Parnassus Investments CA, Amundi Pioneer Asset Management Inc., Kiltearn Partners LLP, American Century Companies Inc. and Geode Capital Management LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen. How do I buy shares of Biogen? Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Biogen's stock price today? One share of BIIB stock can currently be purchased for approximately $325.61. How big of a company is Biogen? Biogen has a market capitalization of $64.05 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe. What is Biogen's official website? The official website for Biogen is http://www.biogen.com. How can I contact Biogen? Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected] MarketBeat Community Rating for Biogen (NASDAQ BIIB)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 1,506 (Vote Outperform)Underperform Votes: 866 (Vote Underperform)Total Votes: 2,372MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: How Do Tariffs Affect Trade Balances?